• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Satori Pharmaceuticals

edit

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders.

Recent Milestones

edit

• 
  Satori Pharmaceuticals received $15M in Venture Round funding. (2/23/12)
  Posted 2/23/12 at 5:56am via finsmes.com
• 
  Satori Pharmaceuticals — has raised $7 million in a new round of financing that is targeting $20 million (1/4/11)
  Posted 1/5/11 at 7:14am via masshightech.com
• 
  Satori Pharmaceuticals received $22M in Series A funding. (1/8/09)
  Posted 11/10/09 at 11:40am via satoripharma.com
• 
  Satori Pharmaceuticals received $3M in Seed funding. (1/1/05)
  Posted 11/10/09 at 11:40am via satoripharma.com
• 
  Satori Pharmaceuticals added Jeffrey Ives as CEO, Board of Directors.
  Posted 11/10/09 at 11:38am
• 
  Satori Pharmaceuticals added Mark Findeis as Co-Founder, Senior VP Research.
  Posted 11/10/09 at 11:38am
• 
  Satori Pharmaceuticals added Brian Bronk as VP Chemistry.
  Posted 11/10/09 at 11:38am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 2/24/12

Sources

1. Satori (satoripharma.com) [edit]
2. Satori (satoripharma.com) [edit]
3. Satori Pharmaceuticals Raises $15M (finsmes.com) [edit]
Satori socks away $7M in new $20M funding (masshightech.com) [edit]